* La Jolla Pharmaceutical Co., of San Diego, said that itsinvestigational new drug application for LJP 394, its lead compound totreat lupus, cleared the FDA without requests for changes, and humantrials should start in a matter of weeks.* CV Therapeutics, of Palo Alto, Calif., signed an exclusive,worldwide license to adenosine receptor antagonists and agonistsdiscovered at the University of Florida and the University of SouthFlorida.* AgriDyne Technologies Inc., of Salt lake City, entered into anexclusive license with the Rohm and Haas Co. for certain technologiesrelated to bioinsecticides derived from the neem tree.* Elan Corp. plc, of Ireland, Dura Pharmaceuticals Inc., of San Diego,and Dura Delivery Systems Inc. signed agreements resulting in theformation of a strategic alliance. One of the agreements gives Elanrights to market eight respiratory compounds outside the U.S. for use inthe Dryhaler drug delivery system.

(c) 1997 American Health Consultants. All rights reserved.